Pfizer Lyme vaccine shows more than 70% efficacy but misses key statistical goal

There hasn't been an approved Lyme disease vaccine for more than 20 years, after GSK pulled its shot due to a lack of demand.

Pfizer Stock Is Doing Something It Hasn't Done Since 2022

Up until recently, the stock has been a chronic underperformer.

Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial

Pfizer (NYSE:PFE) has quietly built momentum in 2026, with shares up 6.61% year-to-date and 2.70% over the past year. The stock is currently trading near $26.84 but remains well below its 52-week high of $27.

Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts

Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, May 5, 2026. The purpose of the call is to provide an update on Pfizer’s results,

Pfizer vs Moderna: Which Pharma Stock Has More Upside?

They aren't just "pandemic stocks."

Pfizer’s oral CDK4 inhibitor shows promise in second-line breast cancer

Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.